Fig. 5

Birmingham Vasculitis Activity Scores from the time of disease diagnosis to before mepolizumab treatment initiation, during treatment, or at the last visit while on mepolizumab, in EGPA patients in the super-responder group (a) and the responder group (b). Each line represents mean scores. Mean values for each patient group were compared by using the Wilcoxon matched-pairs t-test; p < 0.05 was considered statistically significant. †p < 0.01. Upper brackets at the top show the significance of differences between diagnosis versus initiation of mepolizumab treatment and years 1, 2, 3, and last examination during mepolizumab treatment; lower brackets show the significance of differences between initiation of mepolizumab treatment versus years 1, 2, 3, and last examination